Alcanza Clinical Research Expands National Network with Acquisition of Tampa Bay Medical Research

Alcanza Clinical Research has acquired Tampa Bay Medical Research, an independent clinical research center with nearly four decades of operation in Florida's Tampa Bay region. The acquisition brings TBMR's extensive experience in conducting over 600 clinical trials across multiple therapeutic areas into Alcanza's growing national network. This strategic move enhances Alcanza's ability to provide clinical trial opportunities to diverse patient populations while maintaining the local expertise that has characterized TBMR's operations since its founding in 1984.

The integration of TBMR's facilities, which total over 5000 square feet across Clearwater and Largo locations, expands Alcanza's physical presence in Florida. TBMR has established itself as a trusted partner for both community participants and global pharmaceutical and medical device sponsors through its patient-centric research environment and commitment to high-quality clinical data. The center's multidisciplinary team, led by CEO and Medical Director Sureka Bollepalli, MD, brings specialized expertise in metabolic research and clinical trial execution that will complement Alcanza's existing capabilities.

Carlos Orantes, CEO at Alcanza Clinical Research, emphasized the strategic importance of the acquisition, stating that partnering with high-quality clinical research businesses remains a top priority for the organization. Dr. Bollepalli expressed enthusiasm about the partnership, noting that joining Alcanza will strengthen TBMR's ability to support patients, deepen community engagement, and expand access to high-quality clinical research opportunities. This alignment of missions creates a foundation for advancing medical care and improving patient outcomes through enhanced research capabilities.

The acquisition represents a significant step in Alcanza's mission to expand its national footprint while preserving the local expertise and personalized care that research participants value. By combining TBMR's operational excellence and established community presence with Alcanza's scalable infrastructure and strategic partnerships, the organization aims to accelerate clinical research timelines and broaden patient access to innovative treatment opportunities. This integration supports Alcanza's focus on bringing clinical trial opportunities involving life-changing treatments and vaccines to all patients, particularly those from underrepresented communities who have historically had limited access to research participation.

Alcanza Clinical Research operates an integrated network of research facilities that includes 25 dedicated research units and additional integrated specialty clinic sites strategically located throughout multiple regions. The organization supports studies across all trial phases and major therapeutic areas, with the TBMR acquisition strengthening its presence in the Southeast region. More information about Alcanza's research network can be found at https://alcanzaclinical.com. The combined resources of both organizations are expected to enhance clinical trial diversity, improve research efficiency, and contribute to the development of new medical treatments through expanded patient access and operational capabilities.